Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 4,780,000 shares, an increase of 13.8% from the March 31st total of 4,200,000 shares. Based on an average daily trading volume, of 256,300 shares, the short-interest ratio is currently 18.7 days.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CUE. Stifel Nicolaus reaffirmed a “buy” rating and issued a $8.00 price target on shares of Cue Biopharma in a research report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Cue Biopharma in a report on Tuesday, April 9th. Jefferies Financial Group started coverage on shares of Cue Biopharma in a report on Wednesday, March 13th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $8.00 price objective on shares of Cue Biopharma in a report on Wednesday, April 3rd.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Wedmont Private Capital grew its stake in shares of Cue Biopharma by 100.0% during the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after purchasing an additional 20,000 shares during the period. Legacy Capital Group California Inc. bought a new position in shares of Cue Biopharma in the 4th quarter worth approximately $26,000. Navalign LLC purchased a new position in shares of Cue Biopharma in the fourth quarter worth approximately $66,000. Finally, Sigma Planning Corp grew its position in Cue Biopharma by 8.6% during the third quarter. Sigma Planning Corp now owns 244,705 shares of the company’s stock valued at $563,000 after buying an additional 19,405 shares during the period. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Stock Performance

CUE traded up $0.05 during midday trading on Monday, hitting $1.42. 155,919 shares of the company traded hands, compared to its average volume of 263,803. The company’s 50-day moving average is $1.85 and its 200 day moving average is $2.29. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $69.07 million, a PE ratio of -1.29 and a beta of 2.02. Cue Biopharma has a 52 week low of $1.30 and a 52 week high of $5.12.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Monday, April 8th. The company reported ($0.28) earnings per share for the quarter. Cue Biopharma had a negative net margin of 924.10% and a negative return on equity of 112.26%. The company had revenue of $1.82 million for the quarter. On average, research analysts expect that Cue Biopharma will post -1 EPS for the current year.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.